Novo Nordisk A/S says FDA extends denecimig review over facility remediation
The company says the agency has set no new action date, while its U.S. launch target remains conditional on approval.
Adrian Kessler
An anticipated U.S. approval window has passed without a decision as Novo Nordisk A/S NYSENVO said in an Oct. 2 announcement that manufacturing remediation has extended the FDA review of denecimig for haemophilia A. Novo had expected an action in the third quarter of 2026, but the agency has given it no revised date.
Novo submitted the biologics licence application in September 2025 for adults and children, including patients with factor VIII inhibitors. The FDA conducted a pre-licence inspection of the manufacturing site, then told Novo that ongoing remediation there was the reason its review would take longer. The company gave no completion date for that work.
Novo is a Danish healthcare company developing and selling medicines globally, including treatments for inherited blood disorders.
Novo's U.S. shares NYSENVO closed Wednesday at US$37.91 as of 4:00:06 p.m. EDT in New York, according to the quote available for this story. That quotation predates the Oct. 2 announcement, so it cannot establish how the shares responded to the delay.
Facility Work Extends The FDA Review
Novo said the FDA had identified no deficiencies in the clinical efficacy or safety data submitted with the application. The company described the remaining work as remediation at the manufacturing facility and said it was addressing the agency's requests. Its announcement gives neither a date for completing the fixes nor a new FDA action date.
Denecimig is a bispecific antibody designed to mimic activated factor VIII by bringing clotting factors IXa and X together. It is injected under the skin, and Novo has studied weekly, every-two-weeks and monthly schedules. The intended population includes people with haemophilia A who have developed inhibitors against factor VIII treatment.
The FRONTIER programme includes separate studies in adults and adolescents and in younger children, plus an open-label extension to assess longer-term safety. FRONTIER2 studied monthly and weekly dosing in people aged 12 and older; FRONTIER3 studied those schedules in children under 12. FRONTIER4 is evaluating dosing every two weeks and safety across the schedules. The Oct. 2 announcement provided no new bleeding-rate results.
"Novo is already in the process of addressing the FDA's requests as efficiently as possible and continuing to work closely with the Agency toward bringing denecimig to patients in the US." Novo chief executive Mike Doustdar said in the announcement.
The longer review does not change Novo's 2026 financial outlook or affect its other marketed products, the company said. Denecimig received a positive opinion from Europe's CHMP on Sept. 17, while European marketing approval remains pending. That opinion does not set a U.S. decision date.
Read more: Novo Nordisk reports normal liver fat in 23 of 26 Wegovy users
Roche And Pfizer Already Sell Preventive Injections
Roche Holding AG OTCMKTSRHHBY said in its Oct. 3, 2018 U.S. approval notice that Hemlibra is approved to prevent or reduce bleeding in people with haemophilia A, with or without factor VIII inhibitors. Its injection schedule can be weekly, every two weeks or every four weeks. A monthly denecimig regimen would therefore enter a market that already has that dosing interval, if the FDA approves it.
Pfizer Inc. NYSEPFE said in its June 8, 2026 approval notice that Hympavzi is approved for haemophilia A or B prophylaxis in patients aged six and older, with or without inhibitors. Pfizer says the medicine is injected under the skin once a week. Novo's eventual U.S. label, if granted, will determine which patients it can address alongside those treatments.
At the Friday close, the iShares Biotechnology ETF NASDAQIBB was US$205.29 on Nasdaq as of 4:00:01 p.m. EDT. That sector quote provides a same-day price, while Novo's available quote stops before the announcement.
Read more: Wave Life Sciences plans two-year WVE-006 trial after FDA feedback
Novo still aims for a U.S. launch in the first half of 2027, conditional on an FDA decision. The agency has provided no new action date, making completion of the facility remediation the next step Novo must clear before that launch window can be tested.
